On Aug. 19, 2020, Sorrento announced that it had filed an investigational new drug application (IND) for COVI-GUARD (STI-1499) for hospitalized COVID-19 patients. Animal data generated at the University of Texas Medical Branch at Galveston Syrian Golden Hamsters infected with SARS-CoV-2, justified the IND filing and continued clinical development.